达罗他胺对比阿帕他胺与恩扎卢胺治疗高危非转移性去势抵抗性前列腺癌的总生存与不良事件:系统综述与网络Meta分析
该系统综述与网络Meta分析基于SPARTAN、PROSPER和ARAMIS三项随机试验的4117例观察数据,比较三种指南推荐的高危nmCRPC治疗方案。结果显示达罗他胺在总生存获益和3级以上不良事件方面排名最优,但在PSA-DT≤6个月亚组中恩扎卢胺疗效排名第一。研究设计、人群和随访时长差异可能影响解读。
要点
- 达罗他胺在总生存获益和3级以上不良事件方面均排名第一。
- PSA-DT≤6个月亚组中恩扎卢胺总生存排名第一。
- PSA-DT 6-10个月亚组中达罗他胺总生存排名第一。
核心结论
- 当前网络Meta分析提示达罗他胺具有最高的总生存疗效和最低的3级以上毒性。
- 在PSA-DT≤6个月亚组中,恩扎卢胺记录到最高疗效。
研究设计与样本
- 系统综述与网络Meta分析,遵循PRISMA,检索PubMed获取SPARTAN、PROSPER和ARAMIS三项前瞻性随机试验的最新报告。
- 数据来源于三项试验的4117例观察,总生存为主要结局,不良事件为次要结局。
主要发现
- 相对ADT的总生存获益排名:达罗他胺第一,恩扎卢胺第二,阿帕他胺第三。
- PSA-DT≤6个月亚组总生存排名:恩扎卢胺第一,达罗他胺第二,阿帕他胺第三。
- PSA-DT 6-10个月亚组总生存排名:达罗他胺第一,阿帕他胺第二,恩扎卢胺第三。
- 3级以上不良事件排名:达罗他胺最优,恩扎卢胺次之,阿帕他胺第三。
临床怎么用
- 高危nmCRPC治疗选择可参考达罗他胺在总生存和3级以上毒性方面的网络Meta分析排名。
- PSA-DT≤6个月患者可考虑恩扎卢胺在总生存方面的亚组排名优势。
局限性
- 研究设计、研究人群和随访时长是三项研究间的潜在关键差异,网络Meta分析方法未能进行统计学校正。
- 这些差异在解读当前及任何网络Meta分析时应予以充分考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives. METHODS: We performed a systematic review and network meta-analysis focusing on OS and AE according to the most recent apalutamide, enzalutamide, and darolutamide reports. We systematically examined and compared apalutamide vs. enzalutamide vs. darolutamide efficacy and toxicity, relative to ADT according to PRISMA. We relied on PubMed search for most recent reports addressing prospective randomized trials with proven predefined OS benefit, relative to ADT: SPARTAN, PROSPER, and ARAMIS. OS represented the primary outcome and AEs represented secondary outcomes. RESULTS: Overall, data originated from 4117 observations made within the three trials that were analyzed. Regarding OS benefit relative to ADT, darolutamide ranked first, followed by enzalutamide and apalutamide, in that order. In the subgroup of PSA-doubling time (PSA-DT) ≤ 6 months patients, enzalutamide ranked first, followed by darolutamide and apalutamide in that order. Conversely, in the subgroup of PSA-DT 6-10 months patients, darolutamide ranked first, followed by apalutamide and enzalutamide, in that order. Regarding grade 3+ AEs, darolutamide was most favorable, followed by enzalutamide and apalutamide, in that order. CONCLUSION: The current network meta-analysis suggests the highest OS efficacy and lowest grade 3+ toxicity for darolutamide. However, in the PSA-DT ≤ 6 months subgroup, the highest efficacy was recorded for enzalutamide. It is noteworthy that study design, study population, and follow-up duration represent some of the potentially critical differences that distinguish between the three studies and remained statistically unaccounted for using the network meta-analysis methodology. Those differences should be strongly considered in the interpretation of the current and any network meta-analyses.
引用
- Wenzel M, Nocera L, Collà Ruvolo C, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 34054128. doi:10.1038/s41391-021-00395-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。